Patent intelligence · EP
EP 2791134
CHEMISCHE VERBINDUNG ALS ZWISCHENPRODUKT ZUR HERSTELLUNG EINES CATECHOL-O-METHYLTRANSFERASE-INHIBITORS
CHEMISCHE VERBINDUNG ALS ZWISCHENPRODUKT ZUR HERSTELLUNG EINES CATECHOL-O-METHYLTRANSFERASE-INHIBITORS
Patent details — EP 2791134
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Oct 22, 2014
- Expiration
- Oct 17, 2034
- Applicant
- BIAL PORTELA & Cª S A [PT]
- CPC classes
- A61K 31/ 4425 A I, A61K 31/ 4439 A I, A61P 25/ 16 A I, A61P/2500
Quick answer
EP 2791134 (CHEMISCHE VERBINDUNG ALS ZWISCHENPRODUKT ZUR HERSTELLUNG EINES CATECHOL-O-METHYLTRANSFERASE-INHIBITORS) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Oct 22, 2014. Expires Oct 17, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4425 A I, A61K 31/ 4439 A I, A61P 25/ 16 A I, A61P/2500, A61P/2516, A61P/4300
More from BIAL PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2791134?
EP 2791134 (CHEMISCHE VERBINDUNG ALS ZWISCHENPRODUKT ZUR HERSTELLUNG EINES CATECHOL-O-METHYLTRANSFERASE-INHIBITORS) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Oct 22, 2014. Expires Oct 17, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2791134?
BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does EP 2791134 expire?
Our index shows an expiration date of Oct 17, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.